Stay updated on Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial

Sign up to get notified when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    Updated revision from v3.0.1 to v3.0.2; removed the 'Back to Top' element.
    Difference
    0.2%
    Check dated 2025-09-13T17:36:05.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1.
    Difference
    0.2%
    Check dated 2025-09-06T14:49:15.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The web page has been updated to include a new facility name and location, along with a list of publications related to multiple myeloma, while several previous location details and related topics have been removed.
    Difference
    6%
    Check dated 2025-08-30T11:40:26.000Z thumbnail image
  4. Check
    22 days ago
    No Change Detected
  5. Check
    29 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.1%
    Check dated 2025-08-16T04:35:27.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.10 to version 2.16.11.
    Difference
    0.1%
    Check dated 2025-08-08T23:54:12.000Z thumbnail image
  7. Check
    43 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a service alert regarding planned maintenance has been removed.
    Difference
    0.8%
    Check dated 2025-08-01T19:25:54.000Z thumbnail image

Stay in the know with updates to Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.